24/7 Newsfeed

Put Reason 24/7 on Your Site

RSS

Follow Reason 24/7 on Twitter and via RSS

Merck, GE to Collaborate on Alzheimer's Drug

Merck & Co and General Electric Co's healthcare unit have agreed to collaborate on an experimental drug for Alzheimer's disease, the companies said on Tuesday.

GE Healthcare will supply Flutemetamol, an investigational imaging agent, to Merck for use with its experimental Alzheimer's disease drug MK-8931.

The companies hope GE's imaging agent will help identify patients who might benefit from a therapy such as Merck's, which targets beta amyloid, a protein that can clump together and form plaques in the brain. Such plaques have been found in the brains of patients with Alzheimer's disease.

Source: Reuters. Read full article. (link)

Editor's Note: We invite comments and request that they be civil and on-topic. We do not moderate or assume any responsibility for comments, which are owned by the readers who post them. Comments do not represent the views of Reason.com or Reason Foundation. We reserve the right to delete any comment for any reason at any time. Report abuses.

advertisement